EIF4G1 and prostate cancer: Our analysis of survival data revealed that Brain lower grade glioma, kidney, liver, lung, mesothelioma, pancreatic, prostate cancer, sarcoma and skin cutaneous melanoma patients with high EIF4G1 expression had significantly (p-value: p < 0.0001, p = 0.01, p < 0.0001, p = 0.00016, p = 0.0043, p = 0.015, p = 0.036, p = 0.0052, p = 0.052 respectively) lower median survival compared to the patient with low/Medium EIF4G1 expression (Fig. 7a–i, Additional file 1: Table S1).